<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114313">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615029</url>
  </required_header>
  <id_info>
    <org_study_id>CR101391</org_study_id>
    <secondary_id>GEN503</secondary_id>
    <secondary_id>DARA-GEN503</secondary_id>
    <secondary_id>2011-005709-62</secondary_id>
    <nct_id>NCT01615029</nct_id>
  </id_info>
  <brief_title>Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma</brief_title>
  <official_title>An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety profile of daratumumab when given in
      combination with Lenalidomide and dexamethasone in participants with relapsed or relapsed
      and refractory Multiple Myeloma (MM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is conducted in two parts. The dose escalation portion of the trial (Part 1)
      participants are enrolled into cohorts at increasing dose levels of daratumumab in
      combination with Len/Dex in 28 day treatment cycles. Part 2, the cohort expansion part of
      the trial, will further explore the maximum tolerated dose (MTD) (or the maximum tested
      dose) of daratumumab as determined in Part 1.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 and 2: Number of participants with adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Number of participants with objective response</measure>
    <time_frame>End of the Treatment (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
    <description>Objective response rate (ORR) will be measured using the international uniform response criteria for multiple myeloma. ORR is defined as the number of participants with tumor size reduction of a predefined amount and for a minimum time period. The subcategories of ORR are complete response, stringent complete response, very good partial response, partial response, minimal response, and stable disease. ORR is sum of complete and partial responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Area under the concentration-time curve of daratumumab</measure>
    <time_frame>Predose and up to 12hrs for Cycle 1;predose and up to 2hrs for Cycle 2;predose and end of daratumumab infusion for Cycles 3 to 24;monthly for follow-up visits (up to 6 months);and at end of treatment visit (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Maximum observed concentration of daratumumab</measure>
    <time_frame>Predose and up to 12hrs for Cycle 1;predose and up to 2hrs for Cycle 2;predose and end of daratumumab infusion for Cycles 3 to 24;monthly for follow-up visits (up to 6 months);and at end of treatment visit (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Minimum observed concentration of daratumumab</measure>
    <time_frame>Predose and up to 12hrs for Cycle 1;predose and up to 2hrs for Cycle 2;predose and end of daratumumab infusion for Cycles 3 to 24;monthly for follow-up visits (up to 6 months);and at end of treatment visit (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Time to reach the maximum plasma concentration of daratumumab</measure>
    <time_frame>Predose and up to 12hrs for Cycle 1;predose and up to 2hrs for Cycle 2;predose and end of daratumumab infusion for Cycles 3 to 24;monthly for follow-up visits (up to 6 months);and at end of treatment visit (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Apparent clearance of daratumumab</measure>
    <time_frame>Predose and up to 12hrs for Cycle 1;predose and up to 2hrs for Cycle 2;predose and end of daratumumab infusion for Cycles 3 to 24;monthly for follow-up visits (up to 6 months);and at end of treatment visit (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Volume of distribution of daratumumab</measure>
    <time_frame>Predose and up to 12hrs for Cycle 1;predose and up to 2hrs for Cycle 2;predose and end of daratumumab infusion for Cycles 3 to 24;monthly for follow-up visits (up to 6 months);and at end of treatment visit (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Half-life of daratumumab</measure>
    <time_frame>Predose and up to 12hrs for Cycle 1;predose and up to 2hrs for Cycle 2;predose and end of daratumumab infusion for Cycles 3 to 24;monthly for follow-up visits (up to 6 months);and at end of treatment visit (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Time taken for progression of disease</measure>
    <time_frame>End of the Treatment (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Duration of response</measure>
    <time_frame>End of the Treatment (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
    <description>Response duration is defined as the number of days from the first observation where the participant meets the criteria for response to the time where the participant's disease progresses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Participants with progression free survival</measure>
    <time_frame>End of the Treatment (3 to 5 Weeks After the Last Dose of Study Drug)</time_frame>
    <description>Progression free survival is the time period from start of study medication till the disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Daratumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive daratumumab along with Lenalidomide and dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1 (Dose Escalation): Daratumumab</intervention_name>
    <description>Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.</description>
    <arm_group_label>Daratumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2 (Dose Expansion): Daratumumab</intervention_name>
    <description>Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.</description>
    <arm_group_label>Daratumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.</description>
    <arm_group_label>Daratumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously [injection of a substance into a vein]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index [BMI] less than [&lt;] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.</description>
    <arm_group_label>Daratumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (Part 1) Have relapsed multiple myeloma after receiving a minimum of 2 and a maximum
             of 4 prior lines of therapy and be eligible for treatment with lenalidomide and
             dexamethasone (Len/Dex)

          -  (Part 2) Have received at least 1 prior line of therapy for multiple myeloma

          -  Be older than or be 18 years of age

          -  Eastern Cooperative Oncology Group (ECOG) performance status (0-2)

          -  Provide signed informed consent after receipt of oral and written information about
             the study and before any study-related activity is performed

        Exclusion Criteria:

          -  Have previously received an allogenic stem cell transplant

          -  Have received autologous stem cell transplant within 12 weeks before the first
             infusion

          -  Have received antimyeloma treatment, radiotherapy, or any experimental drug or
             therapy within 2 weeks before the first infusion

          -  Have discontinued lenalidomide due to any treatment-related adverse event or be
             refractory to any dose of lenalidomide. Refractory to lenalidomide is defined as
             either, participants whose disease progresses within 60 days of lenalidomide, or
             participants whose disease is nonresponsive while on any dose of lenalidomide.
             Nonresponsive disease is defined as either failure to achieve at least an minimal
             response (MR) or development of progressive disease (PD) while on lenalidomide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torben Plesner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Richardson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana Farber</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen Ã˜</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>June 6, 2012</firstreceived_date>
  <firstreceived_results_disposition_date>September 7, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Dose-escalation</keyword>
  <keyword>Relapsed multiple myeloma</keyword>
  <keyword>Relapsed and refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
